Very late onset lymphoproliferative disorders occurring over 10 years post-renal transplantation

Khedmat, Hossein; Taheri, Saeed

doi:10.5144/1658-3876.2011.73

Cited by 14 publications

(19 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The histological types were Burkitt lymphoma, diffuse large B cell lymphoma, and Hodgkin-type PTLD. Though all individual cases were unique in their presentation, our series reflected the heterogenous presentation of late PTLDs that was described in other published case reports and series [1,5,7].…”

Section: Discussionsupporting

confidence: 57%

“…Interestingly, recent studies have proposed that earlyand late-onset PTLD affect different populations, have different morphologic characteristics, and have different behaviors [2,3,5]. Because our cases are examples of late-onset PTLD, we will focus on this subgroup.…”

Section: Discussionmentioning

confidence: 99%

“…The incidence of PTLD again rises 4-5 years after SOT, and the mechanisms involving clonal proliferation in late PTLDs are obscure. Late-onset PTLD occurs within 2-10 years after SOT [1,3,4] and very late-onset PTLD occurs more than 10 years after transplantation [5].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Late-Onset Posttransplant Lymphoproliferative Disorders after Solid Organ Transplantation in Adults: A Case Series and Review of the Literature

Gandhi¹,

Behling

D³

et al. 2020

Case Reports in Transplantation

View full text Add to dashboard Cite

The posttransplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of neoplasms that have wide variety of clinical and histological presentations. The management of PTLDs is challenging due to variety of involvement sites and histological types. The length and type of immunosuppression are correlated with the emergence of PTLDs, and most of the cases appear within the first two years after transplant. This case series describes five late-onset PTLDs with rare histological features and multiorgan involvement.

show abstract

Section: Discussionsupporting

confidence: 57%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Late-Onset Posttransplant Lymphoproliferative Disorders after Solid Organ Transplantation in Adults: A Case Series and Review of the Literature

Gandhi¹,

Behling

D³

et al. 2020

Case Reports in Transplantation

View full text Add to dashboard Cite

show abstract

“…Some cases can take more than 10 years, and investigators have introduced a new category for cases with onset of more than 10 years between transplantation and PTLD appearance: very late onset. It represents a distinct clinicopathological subset, occurring more frequently in older patients with a long latency period, EBV-negativity, and with poor response to treatment and worse prognosis [4]. Our case fits in this rare category, as the patient was EBV-negative, developed lymphoma after almost a decade of transplantation, and had a poor outcome.…”

Section: Discussionmentioning

confidence: 61%

Plasmablastic Lymphoma Found on Autopsy in a Post-Transplant Patient

Abbas

Goyal

Noory

et al. 2020

Cureus

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is an aggressive lymphoma often seen in immunodeficient patients. It can be a diagnostic challenge given its high-grade appearance and lack of staining for traditional B-cell markers. We present an interesting case of a 65-year-old African-American female who presented to the emergency department (ED) with complaints of progressively worsening weakness, fatigue, and dizziness for one month, and dark-colored urine for three days. The patient's medical history was remarkable for a renal and pancreatic transplant in 2008.

show abstract

“…In the current study, 2 of our findings might be considered predictors for a better outcome for CD20-positive PTLD patients: the higher share of early onset PTLD and the lower rate of bone marrow involvement. However, a previous study of ours showed no survival advantage for early onset PTLD in renal recipients, 50 but bone marrow involvement was a predictor for lower outcome (unpublished data). Our finding about the inferior outcome of PTLD in renal recipients expressing the CD20 antigen on their tumor cells cannot be explained by simultaneous characteristics and seems to be independent.…”

Section: Discussionmentioning

confidence: 75%

CD20 Antigen Expression by Lymphoproliferative Disorders after Kidney Transplant is Independently Associated with a Poor Outcome: PTLD.Int Survey

Khedmat

Taheri²

2012

Exp Clin Transplant

Self Cite

View full text Add to dashboard Cite

Objectives: Antigen expression by neoplastic cells is important because of its effects on the behavior and survival of patients. We sought to gather data on renal transplant recipients who had developed posttransplant lymphoproliferative disorders in their posttransplant era, and had a documented report on CD20 antigen testing. Materials and Methods: A comprehensive search of the literature was done for reports that indicate test results for the CD20 antigen in kidney recipients having lymphoproliferative disorders after transplant. Their demographics, disease characteristics, and prognoses were analyzed. Results: CD20-positive posttransplant lymphoproliferative disorder patients had a significantly shorter time from transplant to developing posttransplant lymphoproliferative disorder (P < .001). None of patients who had early onset posttransplant lymphoproliferative disorder was CD20 negative. Bone marrow involvement was significantly more prevalent among CD20-negative patients (P < .05) with no CD20-positive patient developing a bone marrow metastasis. Log-rank test showed a relatively worse survival for renal recipients expressing the CD20 antigen (P = .07). Conclusions: CD20-positive posttransplant lymphoproliferative disorder lesions in kidney transplant patients are significantly more likely to develop early after transplant and represent an inferior outcome.We suggest that all renal transplant recipients who develop posttransplant lymphoproliferative disorder within their early time after surgery should be given anti-CD20 therapy. Future prospective studies are required to confirm our conclusions.

show abstract

Very late onset lymphoproliferative disorders occurring over 10 years post-renal transplantation

Abstract: Older renal transplant patients are at increased risk for development of very late onset PTLD, and should be strictly followed. further multi-institutional prospective studies are needed to confirm our results.

Cited by 14 publications

References 43 publications

Late-Onset Posttransplant Lymphoproliferative Disorders after Solid Organ Transplantation in Adults: A Case Series and Review of the Literature

Late-Onset Posttransplant Lymphoproliferative Disorders after Solid Organ Transplantation in Adults: A Case Series and Review of the Literature

Plasmablastic Lymphoma Found on Autopsy in a Post-Transplant Patient

CD20 Antigen Expression by Lymphoproliferative Disorders after Kidney Transplant is Independently Associated with a Poor Outcome: PTLD.Int Survey

Contact Info

Product

Resources

About